Login / Signup

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.

James J SteinhardtJavier GuenagaHannah L TurnerKrisha McKeeMark K LouderSijy O'DellChi-I ChiangLin LeiAndrey GalkinAlexander K AndrianovNicole A Doria-RoseRobert T BailerAndrew B WardJohn R MascolaYuxing Li
Published in: Nature communications (2018)
HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a "single" agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity.
Keyphrases